01—Abstract
Summary
Summary of the 8-K filed January 22, 2026. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories reported fourth-quarter and full-year 2025 results on January 22, 2026, with sales of $11.46 billiona in Q4 (up 4.4% reported, 3.0% organic) and $44.3 billion for the full year (up 5.7% reported, 5.5% organic).
Adjusted diluted EPS rose 12% to $1.50b in Q4 and 10% to $5.15 for the full year, while GAAP diluted EPS was $1.01 in Q4 and $3.72 for 2025. The GAAP-to-adjusted gap reflects roughly $854 million of after-tax Q4 specified items, including $422 million of intangible amortization and a $165 million legal reserve. Full-year GAAP EPS is also depressed versus 2024, which was inflated by a $7.5 billion non-cash tax valuation allowance release, so year-over-year GAAP comparisons are not meaningful.
The quarter was mixed by segment. Medical Devices was the clear bright spot, growing 10.4% organically in Q4 and 11.9% for the year, led by Electrophysiology, Heart Failure, Diabetes Care and Rhythm Management, with continuous glucose monitor sales of $2.0 billionc in the quarter. Nutrition declined 9.1% organically in Q4 on lower volumes and strategic price actions, and Diagnostics fell 3.6% organically as COVID-19 testing revenue shrank and China faced volume-based procurement pressure.
Established Pharmaceuticals grew 7.0% organically. Management's 2026 guidance calls for 6.5% to 7.5% organic sales growth and adjusted EPS of $5.55 to $5.80d, roughly 10% growth at the midpoint, with Q1 2026 adjusted EPS of $1.12 to $1.18. Strategically, Abbott expects to close its pending acquisition of Exact Sciences in the second quarter of 2026, which would give it a foothold in cancer diagnostics.
The company also launched its first pulsed field ablation system in the U.S. (Volt) and received CE Mark for a PFA-enabled catheter, strengthening its Electrophysiology position. The board declared a $0.63 quarterly dividend, the 408th consecutive quarterly payment and the 54th year of dividend increases.
02—Key points
Key Highlights
- Q4 2025 sales of $11.46B grew 4.4% reported and 3.0% organic; full-year sales of $44.3B grew 5.7% reported and 5.5% organic.
- Adjusted diluted EPS grew 12% to $1.50 in Q4 and 10% to $5.15 for FY2025; GAAP diluted EPS was $1.01 in Q4 and $3.72 for the year.
- Medical Devices was the growth engine, up 10.4% organically in Q4 and 11.9% for FY2025, with Electrophysiology, Heart Failure and Diabetes Care leading.
- Nutrition fell 9.1% organically in Q4 due to lower volumes and strategic price cuts, and Diagnostics fell 3.6% as COVID-19 testing declined and China pricing pressure persisted.
- 2026 guidance: 6.5%–7.5% organic sales growth and adjusted diluted EPS of $5.55–$5.80 (about 10% growth at midpoint); Q1 2026 adjusted EPS of $1.12–$1.18.
- Pending Exact Sciences acquisition, expected to close in Q2 2026, would establish Abbott in the fast-growing cancer diagnostics market.
- Abbott launched its first U.S.-approved pulsed field ablation system (Volt) and obtained CE Mark for a PFA/RF catheter, and declared a $0.63 quarterly dividend.
03—Questions
Frequently Asked Questions
Why is there such a large gap between GAAP and adjusted EPS?
Adjusted EPS excludes about $854 million of after-tax Q4 2025 specified items, equal to $0.49 per share. The largest components are $422 million of intangible amortization, a $165 million legal reserve tied to a settlement, and restructuring, acquisition-related and other charges. Investors should weigh GAAP results alongside these non-GAAP figures, since the company says these items recur in various forms.
Why did GAAP EPS fall so sharply from 2024 to 2025?
The 2024 GAAP figures include a $7.5 billion non-cash tax benefit from releasing valuation allowances tied to restructured foreign affiliates. Q4 2024 GAAP EPS of $5.27 and FY2024 GAAP EPS of $7.64 were inflated by that item, so the 2025 decline is largely a comparison effect rather than an operating deterioration. Adjusted EPS, which excludes that benefit, grew 10% for the year.
What is driving the divergence between Medical Devices and Nutrition/Diagnostics?
Medical Devices benefits from strong demand in Electrophysiology, Heart Failure, Diabetes Care and Rhythm Management, with CGM sales alone near $2.0 billion in Q4. Nutrition is weighed down by lower volumes and deliberate price actions meant to restore future volume growth. Diagnostics is pressured by the decline in COVID-19 testing and weak China market conditions, though core laboratory sales grew.
What does the pending Exact Sciences deal mean for Abbott?
The acquisition is expected to close in Q2 2026 and would give Abbott a leading position in cancer diagnostics, a fast-growing market that complements its existing diagnostics business. Investors should monitor integration, the financing impact and whether the deal's contribution is reflected in the 2026 guidance, which the company did not explicitly detail in this release.
Is Abbott's dividend secure?
Abbott declared a $0.63 quarterly dividend, payable February 13, 2026, to holders of record on January 15, 2026. The company has increased its dividend for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index. Adjusted EPS guidance of $5.55 to $5.80 for 2026 implies solid coverage of the current annual payout of $2.52.
04—Continue